# A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

> **NCT05525247** · PHASE1,PHASE2 · RECRUITING · sponsor: **Selecxine** · enrollment: 420 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SLC-3010
- **COMBINATION_PRODUCT:** Gemcitabine

## Key facts

- **NCT ID:** NCT05525247
- **Lead sponsor:** Selecxine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-21
- **Primary completion:** 2026-02
- **Final completion:** 2028-01
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525247, "A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05525247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*